Biodesix reports preliminary Q4 2021 revenue of $7.2M; core lung testing grows 49% YoY

BIODESIX INC

2022-FY EPS reported -$1.58 revenue$54,506,000

Preliminary full-year 2021 total revenue of $54.5M, up from $45.6M in 2020.
Core lung diagnostic testing revenue grew 49% for full-year 2021.
Quarterly revenue excluding COVID-19 testing was $6.8M, up 22% YoY and 13% QoQ.
Annual revenue excluding COVID-19 testing was $24.3M, up 41% YoY.
Cash and cash equivalents as of Dec 31, 2021: $32.7M; exploring raising capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.